Side Effects and Monitoring After CAR T-Cell Therapy
CAR T-cell therapy works by putting a re-engineered immune system to work against lymphoma, and the side effects that follow are largely a reflection of that immune activity. Unlike chemotherapy, where side effects build gradually over many cycles, the most significant reactions to CAR T-cell therapy tend to appear in a concentrated window — often within the first two weeks after the infusion — and then resolve. Knowing what that window looks like helps patients and caregivers recognize early warning signs, report them promptly, and avoid the uncertainty of wondering whether a symptom is expected or urgent.
Two reactions are described in FDA boxed warnings for approved CAR T-cell products: cytokine release syndrome and neurologic toxicity, sometimes called ICANS. Both are graded using standardized criteria published by the American Society for Transplantation and Cellular Therapy, which lets teams at any center describe severity in the same language and apply the same management steps. Because both can escalate quickly, patients are monitored intensively after infusion and are usually asked to stay within a short distance of the treatment center for a defined period, with a caregiver available around the clock. Many centers provide a thermometer and a symptom diary, and instruct patients to call the 24-hour clinician line for any fever rather than waiting for the next appointment.
Other effects unfold over a longer stretch. Lymphodepleting chemotherapy given before the infusion, plus the therapy's effect on healthy B cells, can leave blood counts and antibody levels low for weeks or months, raising infection risk and sometimes requiring transfusions, growth factors, preventive medications, or immunoglobulin replacement. This is the reason long-term follow-up continues well after remission is documented. Keeping your treatment details — product name, batch or lot number, infusion date, and your treatment center's after-hours number — on hand makes it far easier for any emergency clinician who has never seen your chart to act quickly and correctly.
Cytokine release syndrome (CRS)
As the engineered T cells activate and multiply, they release signaling proteins called cytokines. That immune surge can cause fever, chills, fast heart rate, low blood pressure, and shortness of breath, usually within the first week after infusion. Most cases are mild to moderate and respond to supportive care, fluids, and medicines such as tocilizumab or corticosteroids. Fever is often the very first sign, which is why any temperature after infusion should be reported immediately rather than treated at home.
Neurologic effects (ICANS)
Immune effector cell-associated neurotoxicity syndrome can cause confusion, trouble finding words, tremor, headache, drowsiness, handwriting changes, or, rarely, seizures. Care teams screen for it several times a day using short questions and writing tasks so subtle changes are caught early. Symptoms are usually reversible with monitoring and steroids, but caregivers are often the first to notice them, which is why a caregiver is asked to stay with the patient during the monitoring window.
Low blood counts and infection risk
Low white cells, red cells, and platelets are common after lymphodepleting chemotherapy and can persist for weeks or months. This raises the risk of infection and may require transfusions, growth factors, or preventive antibiotics and antivirals. Because CAR T-cell therapy targeting CD19 also removes healthy B cells, antibody levels can drop, and some patients receive immunoglobulin replacement and need repeat vaccinations later in recovery.
Longer-term follow-up
Patients remain in long-term follow-up so the team can track blood counts, immune recovery, disease response on imaging, and any late effects. Driving and heavy machinery are typically restricted for a period after infusion, and travel is limited until the monitoring window closes. Follow-up schedules vary by product and center.
For educational purposes only. In a medical emergency, call 911 or go to the nearest emergency department.
References
- 1.FDA – Cellular and Gene Therapy Products (boxed warnings for CAR T-cell therapies)
- 2.ASTCT – Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity
- 3.American Cancer Society – CAR T-cell Therapy and Its Side Effects
- 4.National Cancer Institute – CAR T Cells: Engineering Immune Cells to Treat Cancer